MRI-Guided Radiation for Prostate Cancer
Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Male
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: University of Chicago
Disqualifiers: Distant metastases, Prior active treatment, others
No Placebo Group
Approved in 1 Jurisdiction
Trial Summary
What is the purpose of this trial?The purpose of this research is to gather information on the safety and effectiveness of using an imaging technique called magnetic resonance imaging (MRI) to decrease radiation dose to the uninvolved prostate (areas of the prostate that do not clearly have cancer cells) while increasing radiation dose to the nodules (hardened areas of the prostate that have cancer cells).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of MRI-guided radiation treatment for prostate cancer?
MRI is a powerful tool for accurately targeting prostate cancer during radiation therapy, as it provides detailed images of soft tissues. Early clinical experiences suggest that using MRI alone for planning radiation therapy is feasible, although the specific benefits for prostate cancer are still being studied.
12345Is MRI-guided radiation therapy safe for treating prostate cancer?
MRI-guided radiation therapy for prostate cancer has shown promising safety outcomes. In a study of 100 patients, only a few experienced moderate urinary and gastrointestinal side effects, and overall quality of life improved after treatment.
36789How is MRI-guided radiation treatment for prostate cancer different from other treatments?
MRI-guided radiation treatment for prostate cancer is unique because it uses magnetic resonance imaging (MRI) to precisely target the cancer, allowing for more accurate and potentially more effective radiation delivery compared to traditional methods that rely on CT scans. This approach can improve the precision of treatment by better visualizing the prostate and surrounding tissues, potentially reducing side effects and improving outcomes.
13101112Eligibility Criteria
This trial is for men with prostate cancer. Participants should be suitable for radiation treatment and willing to undergo MRI scans. Specific details about inclusion and exclusion criteria are not provided, but typically these would relate to the stage of cancer, overall health, and prior treatments.Inclusion Criteria
My prostate cancer is visible on MRI, without spread beyond the pelvic area.
I am a man over 18 and can care for myself.
Exclusion Criteria
I do not have any other active cancers except for skin cancer.
My doctor thinks I can't safely receive the specific cancer treatment due to other health issues.
My cancer has spread to distant parts of my body.
+6 more
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Radiation
Participants receive MRI scan to identify areas of the prostate for targeted radiation treatment
6-8 weeks
Weekly visits for radiation sessions
Follow-up
Participants are monitored for safety and effectiveness after treatment
12 months
Regular follow-up visits to assess quality of life and side effects
Long-term follow-up
Participants are monitored for biochemical control and long-term outcomes
2 years
Participant Groups
The study is testing if using MRI can help target radiation more precisely in prostate cancer treatment—lowering doses to healthy areas while increasing it where the cancer is concentrated. This could improve safety and effectiveness.
1Treatment groups
Experimental Treatment
Group I: Radiation therapyExperimental Treatment3 Interventions
Participants will receive MRI scan before starting Radiation treatment. The results of this scan will be used to identify areas of the prostate to receive low doses of radiation (areas that show no cancer cells seen by the MRI scan).
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of Chicago Medicine Comprehensive Cancer CenterChicago, IL
Loading ...
Who Is Running the Clinical Trial?
University of ChicagoLead Sponsor
References
MRI-only based radiation therapy of prostate cancer: workflow and early clinical experience. [2019]Magnetic resonance imaging (MRI) is the most comprehensive imaging modality for radiation therapy (RT) target delineation of most soft tissue tumors including prostate cancer. We have earlier presented step by step the MRI-only based workflow for RT planning and image guidance for localized prostate cancer. In this study we present early clinical experiences of MRI-only based planning.
Clinical experience and workflow challenges with magnetic resonance-only radiation therapy simulation and planning for prostate cancer. [2022]Magnetic Resonance (MR)-only planning has been implemented clinically for radiotherapy of prostate cancer. However, fewer studies exist regarding the overall success rate of MR-only workflows. We report on successes and challenges of implementing MR-only workflows for prostate.
Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology. [2022]Prostate cancer is a common malignancy for which radiation therapy (RT) provides an excellent management option with high rates of control and low toxicity. Historically RT has been given with CT based image guidance. Recently, magnetic resonance (MR) imaging capabilities have been successfully integrated with RT delivery platforms, presenting an appealing, yet complex, expensive, and time-consuming method of adapting and guiding RT. The precise benefits of MR guidance for localized prostate cancer are unclear. We sought to summarize optimal strategies to test the benefits of MR guidance specifically in localized prostate cancer.
The value of magnetic resonance imaging in the detection of prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels: a meta-analysis. [2022]To assess the diagnostic performance of magnetic resonance imaging (MRI) for targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen (PSA) levels.
Robotic system for MRI-guided prostate biopsy: feasibility of teleoperated needle insertion and ex vivo phantom study. [2023]Magnetic Resonance Imaging (MRI) combined with robotic assistance has the potential to improve on clinical outcomes of biopsy and local treatment of prostate cancer.
Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. [2022]This study was performed to establish the dose-localization capability and acute toxicity of a real-time intraoperative magnetic resonance (MR) image-guided approach to prostate brachytherapy in select patients with clinically localized prostate cancer.
Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer. [2022]To determine the toxicity reduction required to justify the added costs of MRI-guided radiotherapy (MR-IGRT) over CT-based image guided radiotherapy (CT-IGRT) for the treatment of localized prostate cancer.
Magnetic Resonance-Guided Reirradiation for Local Recurrence Within the Prostate or in the Prostate Bed: Preliminary Results of a Prospective Registry Study. [2022]This prospective registry study evaluated the feasibility of stereotactic magnetic resonance imaging (MRI)-guided radiation therapy for the local treatment of isolated prostate cancer recurrence within the gland or prostate bed after primary radiation therapy.
1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients. [2022]Purpose: The present study reports the preliminary outcomes in terms of adverse events and quality of life in the first 100 patients treated with 1.5T MR-guided daily-adaptive stereotactic body radiotherapy for prostate cancer. Methods: From October 2019 to December 2020, 100 patients, enrolled in a prospective study, received MR-guided SBRT for prostate cancer. Rectal spacer insertion was optional and administered in 37 patients. In total, 32 patients received androgen deprivation therapy in accordance with international guidelines. A prospective collection of data regarding toxicity and quality of life was performed. Results: The median age was 71 years (range, 52-84). The median total dose delivered was 35 Gy (35-36.25 Gy) in five sessions, either on alternate days (n = 25) or consecutive days (n = 75). For acute toxicity, we recorded: seven cases of acute G2 urinary pain and four cases of G2 gastrointestinal events. The median follow-up was 12 months (3-20), recording three late G2 urinary events and one G3 case, consisting of a patient who required a TURP 8 months after the treatment. For gastrointestinal toxicity, we observed 3 G ≥ 2 GI events, including one patient who received argon laser therapy for radiation-induced proctitis. Up to the last follow-up, all patients are alive and with no evidence of biochemical relapse, except for an M1 low-volume patient in distant progression two months after radiotherapy. QoL evaluation reported a substantial resolution of any discomfort within the second follow-up after radiotherapy, with the only exception being sexual items. Notably, after one year, global health items were improved compared to the baseline assessment. Conclusions: This study reports very promising outcomes in terms of adverse events and QoL, supporting the role of 1.5T MR-guided SBRT for prostate cancer. To date, this series is one of the first and largest available in the literature. Long-term results are warranted.
Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy. [2023]Magnetic resonance (MR)-guided radiation therapy (MRgRT) is a new technique for treatment of localized prostate cancer (PCa). We report the 12-month outcomes for the first PCa patients treated within an international consortium (the MOMENTUM study) on a 1.5T MR-Linac system with ultrahypofractionated radiation therapy.
MR-Guided Radiotherapy for Prostate Cancer. [2020]External beam radiotherapy remains the primary treatment modality for localized prostate cancer. The radiobiology of prostate carcinoma lends itself to hypofractionation, with recent studies showing good outcomes with shorter treatment schedules. However, the ability to accurately deliver hypofractionated treatment is limited by current image-guided techniques. Magnetic resonance imaging is the main diagnostic tool for localized prostate cancer and its use in the therapeutic setting offers anatomical information to improve organ delineation. MR-guided radiotherapy, with daily re-planning, has shown early promise in the accurate delivery of radiotherapy. In this article, we discuss the shortcomings of current image-guidance strategies and the potential benefits and limitations of MR-guided treatment for prostate cancer. We also recount present experiences of MR-linac workflow and the opportunities afforded by this technology.
MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. [2019]Magnetic resonance imaging (MRI) provides superior visualization of the prostate and surrounding anatomy, making it the modality of choice for imaging the prostate gland. This pilot study was performed to determine the feasibility and dosimetric quality achieved when placing high-dose-rate prostate brachytherapy catheters under MRI guidance in a standard "closed-bore" 1.5T scanner.